The loss of Cardiovascular Systems on GAAP for the 6 months of fiscal year 2021 was $2.132 million, down 4.5 times from $9.181 million in the previous year. Revenue decreased 6.1% to $124.713 million from $132.824 million a year earlier.
The loss of Cardiovascular Systems on GAAP for the 6 months of fiscal year 2021 was $2.132 million, down 4.5 times from $9.181 million in the previous year. Revenue decreased 6.1% to $124.713 million from $132.824 million a year earlier. 
English (US) 